The brand's softest blanket is now available for shoppers to experience in person as Bedsure leans into offline growth
NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Bedsure, a leading home textile brand trusted by millions worldwide, is expanding its in-store presence with its coziest addition yet: the Bedsure GentleSoft® Ribbed Plush Blanket, now available in Target stores nationwide allowing customers to touch, feel, and experience its signature comfort themselves.
Beloved by TikTok for its cloud-like softness, the Bedsure GentleSoft® Ribbed Plush Blanket has quickly become a fan favorite for its ability to elevate everyday comfort—bringing cozy luxury at an affordable price point. Now, with its rollout in Target stores across the country, customers can see firsthand why this blanket has earned a following.
Available in four stylish colorways—Linen, Light Grey, Crystal Pink, and Green—the blanket is designed to seamlessly complement any space. Whether draped over a couch, layered on a bed, or added to a reading nook, the Bedsure GentleSoft® Ribbed Plush Blanket provides instant comfort and an effortlessly cozy look. Each blanket is prewashed three times to protect its integrity, maintain its plush feel, and ensure it holds up through daily use, representing Bedsure's belief in durability and long-term softness in all its products.
"At Bedsure, we believe that comfort is an essential wellness tool, and something that should be an accessible experience for everyone," said Eric Lin, Chief Marketing Officer at Bedsure. "Partnering with Target gives us the opportunity to bring our signature softness and comfort offline and meet the consumers where they are."
Bedsure's expansion into offline channels through partnerships with Target and Belk, showcase Bedsure's ongoing exploration and continued plans to expand into additional brick-and-mortar retail, working to bring essential comfort to even more households nationwide.
The Bedsure GentleSoft® Ribbed Plush Blanket is available in Twin/Twin XL ($30) and Full/Queen ($40) in Target retailers nationwide.
About Bedsure
Founded in 2016, Bedsure is a leading home textile brand with products sold to over 40 million customers worldwide. Bedsure has over 50 bestselling home products in 8 countries and has maintained a compound growth rate of 100% for five consecutive years. While Bedsure has grown into a global company with a diverse range of products to meet various customer needs, its focus on providing comfortable home products and everyday value remains unchanged. For more information, visit Bedsure's official website https://bedsurehome.com/. Stay in touch with Bedsure on social media @bedsurehome.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Bedsure Expands Offline Retail Footprint With Launch of Its GentleSoft® Ribbed Plush Blanket In Targets Nationwide
|
- Global thought leaders presented cutting-edge research at the 2026 International Symposium on Molecular Glue Drug Discovery.
- XtalPi unveils the AI-driven XGlue™ platform to enable rapid, closed-loop molecular glue drug discovery.
- Cross-sector discussions emphasized the need for bridging gaps between academic research, industrial development, and clinical applications.
SHANGHAI, Jan. 29, 2026 /PRNewswire/ -- Recently, XtalPi, a global leader in AI- and robotics-powered drug discovery, successfully concluded its 2026 International Symposium on Molecular Glue Drug Discovery. The event convened leading scientists, biopharma innovators, entrepreneurs, and investors from around the world to explore how emerging technologies are redefining strategies for historically "undruggable" protein targets.
Molecular glue discovery has long relied on serendipity. In his opening remarks, XtalPi Co-founder and CEO Dr. Jian Ma emphasized the need for a fundamental paradigm shift—moving from chance-based discoveries toward a systematic, technology-driven approach enabled by AI, robotics, and global collaboration.
Anchoring this transition, XtalPi Vice President Dr. Yang Xie introduced the company's proprietary XGlue™ platform. XGlue™ integrates physics-based AI modeling to interrogate complex protein–protein interactions with an agentic AI–controlled autonomous synthesis workflow. This closed-loop design–make–test system enables rapid iteration and significantly expands the addressable target space for molecular glue therapeutics, positioning XtalPi at the forefront of next-generation protein degradation.
The symposium featured a series of scientific presentations highlighting the evolution of the field. Prof. Nathanael S. Gray (Stanford University) and Prof. Bruno Correia (EPFL) discussed leveraging chemically induced proximity and computational de novo design to uncover functional interactions beyond the reach of traditional drug discovery. Prof. Ke Ding (Chinese Academy of Sciences) and Dr. Yong Cang (ShanghaiTech University) presented compelling examples of rationally discovered and designed molecular glues addressing critical diseases with significant unmet medical need. Dr. Jianwei Che (Dana-Farber Cancer Institute) and Dr. Liqiang Fu (GluBio) further highlighted how AI-driven methodologies and enabling technologies are improving target selectivity, enhancing molecular potency, and strengthening the safety profile of glue-based therapeutics. From an investment and commercialization perspective, Mr. Peter Zhang (YAFO Capital) outlined strategic pathways for scaling molecular glue therapies across global markets.
The symposium concluded with a cross-sector roundtable on building a sustainable innovation ecosystem for protein degradation. Moderated by Dr. Yang Xie, the discussion brought together leaders from Sanofi, Betta Pharma, GluBio, and other organizations to address the critical gaps between academic discovery, industrial development, and clinical translation. A shared consensus emerged: sustained progress in protein degradation will require deep integration across science, industry, and capital.
As molecular glue therapeutics continue to gain momentum, the convergence of predictive AI and high-throughput automation is accelerating a shift toward logic-driven drug discovery—transforming once-intractable biological targets into viable therapeutic opportunities.
About XtalPi
XtalPi Holdings Limited (XtalPi, 2228.HK) was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries.
- Global thought leaders presented cutting-edge research at the 2026 International Symposium on Molecular Glue Drug Discovery.
- XtalPi unveils the AI-driven XGlue™ platform to enable rapid, closed-loop molecular glue drug discovery.
- Cross-sector discussions emphasized the need for bridging gaps between academic research, industrial development, and clinical applications.
SHANGHAI, Jan. 29, 2026 /PRNewswire/ -- Recently, XtalPi, a global leader in AI- and robotics-powered drug discovery, successfully concluded its 2026 International Symposium on Molecular Glue Drug Discovery. The event convened leading scientists, biopharma innovators, entrepreneurs, and investors from around the world to explore how emerging technologies are redefining strategies for historically "undruggable" protein targets.
Molecular glue discovery has long relied on serendipity. In his opening remarks, XtalPi Co-founder and CEO Dr. Jian Ma emphasized the need for a fundamental paradigm shift—moving from chance-based discoveries toward a systematic, technology-driven approach enabled by AI, robotics, and global collaboration.
Anchoring this transition, XtalPi Vice President Dr. Yang Xie introduced the company's proprietary XGlue™ platform. XGlue™ integrates physics-based AI modeling to interrogate complex protein–protein interactions with an agentic AI–controlled autonomous synthesis workflow. This closed-loop design–make–test system enables rapid iteration and significantly expands the addressable target space for molecular glue therapeutics, positioning XtalPi at the forefront of next-generation protein degradation.
The symposium featured a series of scientific presentations highlighting the evolution of the field. Prof. Nathanael S. Gray (Stanford University) and Prof. Bruno Correia (EPFL) discussed leveraging chemically induced proximity and computational de novo design to uncover functional interactions beyond the reach of traditional drug discovery. Prof. Ke Ding (Chinese Academy of Sciences) and Dr. Yong Cang (ShanghaiTech University) presented compelling examples of rationally discovered and designed molecular glues addressing critical diseases with significant unmet medical need. Dr. Jianwei Che (Dana-Farber Cancer Institute) and Dr. Liqiang Fu (GluBio) further highlighted how AI-driven methodologies and enabling technologies are improving target selectivity, enhancing molecular potency, and strengthening the safety profile of glue-based therapeutics. From an investment and commercialization perspective, Mr. Peter Zhang (YAFO Capital) outlined strategic pathways for scaling molecular glue therapies across global markets.
The symposium concluded with a cross-sector roundtable on building a sustainable innovation ecosystem for protein degradation. Moderated by Dr. Yang Xie, the discussion brought together leaders from Sanofi, Betta Pharma, GluBio, and other organizations to address the critical gaps between academic discovery, industrial development, and clinical translation. A shared consensus emerged: sustained progress in protein degradation will require deep integration across science, industry, and capital.
As molecular glue therapeutics continue to gain momentum, the convergence of predictive AI and high-throughput automation is accelerating a shift toward logic-driven drug discovery—transforming once-intractable biological targets into viable therapeutic opportunities.
About XtalPi
XtalPi Holdings Limited (XtalPi, 2228.HK) was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
XtalPi Convenes Global Experts to Shape the Future of Molecular Glue Drug Discovery: From Serendipity to Precision
